glp-1 news past 2 days Agonists Market Report 2025-2033, By Product, Molecule, and Geo Dr. Jandial breaks down microdosing

You've heard about Ozempic and Wegovy

Any suspected adverse reactions should be reported through the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk)

Integrated claims research by Prime Therapeutics found that while one-year persistence for weight-loss-indicated GLP-1s improved to roughly 63% by 2024likely due to resolving drug shortageslong-term persistence remains a hurdle, with only about 1 in 12 patients remaining on therapy at the three-year mark

Lastly, the experimental conditions that lead to the increase in glucagon and glucagon action on the GLP-1r were specific to having both elevations in glucose and amino acids

As Novo Nordisk launches first FDA-approved oral weight loss medication, independent examination evaluates Ro's direct-to-patient distribution model, pricing transparency, and telehealth access structure for patients exploring Wegovy Pill without insurance NEW YORK, NY, Jan